These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

805 related items for PubMed ID: 17631021

  • 1. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
    Hmiel SP, Canter C, Shepherd R, Lassa-Claxton S, Nadler M.
    Pediatr Transplant; 2007 Aug; 11(5):524-9. PubMed ID: 17631021
    [Abstract] [Full Text] [Related]

  • 2. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 3. Cyclosporine monitoring in the early post-transplant period in pediatric liver transplant recipients.
    Frauca E, Diaz MC, de la Vega A, Hierro L, Camarena C, Muñoz Bartolo G, Díez R, Murcia J, Gámez M, Sanchez Peinado C, López Santamaría M, Andrés I, Jara P.
    Pediatr Transplant; 2007 Aug; 11(5):530-5. PubMed ID: 17631022
    [Abstract] [Full Text] [Related]

  • 4. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
    Rodríguez E, Delucchi MA, Cano F, Valdebenito S, Castillo MC, Villegas R.
    Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
    [Abstract] [Full Text] [Related]

  • 5. Impact of late conversion from C0 to C2 monitoring of microemulsified cyclosporine in pediatric living donor liver transplant recipients.
    Takatsuki M, Chen CL, Chen YS, Wang CC, Lin CC, Yang CH, Yong CC, Liu YW.
    Clin Transplant; 2004 Dec; 18(6):694-9. PubMed ID: 15516246
    [Abstract] [Full Text] [Related]

  • 6. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients.
    Schubert S, Abdul-Khaliq H, Lehmkuhl HB, Hübler M, Abd El Rahman MY, Miera O, Ewert P, Weng Y, Wei H, Krüdewagen B, Hetzer R, Berger F.
    J Heart Lung Transplant; 2006 Jun; 25(6):619-25. PubMed ID: 16730566
    [Abstract] [Full Text] [Related]

  • 7. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
    Büchler M, Chadban S, Cole E, Midtvedt K, Thervet E, Prestele H, Keown P.
    Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
    [Abstract] [Full Text] [Related]

  • 8. Cyclosporine profiling with C2 and C0 monitoring improves outcomes after heart transplantation.
    Barnard JB, Thekkudan J, Richardson S, Bittar MN, Martyszczuck R, Hasan J, Khasati N, Keevil B, Yonan N.
    J Heart Lung Transplant; 2006 May; 25(5):564-8. PubMed ID: 16678036
    [Abstract] [Full Text] [Related]

  • 9. A randomized, controlled trial of C0- Vs C2-guided therapeutic drug monitoring of cyclosporine in stable heart transplant patients.
    Mathias HC, Ozalp F, Will MB, Borland W, Payne C, Kerr M, Lockhart J, Murday AJ.
    J Heart Lung Transplant; 2005 Dec; 24(12):2137-43. PubMed ID: 16364862
    [Abstract] [Full Text] [Related]

  • 10. Cyclosporine C2 levels have impact on incidence of rejection in de novo lung but not heart transplant recipients: the NOCTURNE study.
    Iversen M, Nilsson F, Sipponen J, Eiskjaer H, Mared L, Bergan S, Nyström U, Fagertun HE, Solbu D, Simonsen S.
    J Heart Lung Transplant; 2009 Sep; 28(9):919-26. PubMed ID: 19716045
    [Abstract] [Full Text] [Related]

  • 11. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients.
    Akhlaghi F, Gonzalez L, Trull AK.
    J Heart Lung Transplant; 2005 Dec; 24(12):2120-8. PubMed ID: 16364860
    [Abstract] [Full Text] [Related]

  • 12. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy.
    Cantarovich M, Besner JG, Barkun JS, Elstein E, Loertscher R.
    Clin Transplant; 1998 Jun; 12(3):243-9. PubMed ID: 9642517
    [Abstract] [Full Text] [Related]

  • 13. Assessment of cyclosporine pharmacokinetic parameters to facilitate conversion from C0 to C2 monitoring in heart transplant recipients.
    Davies RA, Veinot JP, Williams K, Haddad H, Baker A, Donaldson J, Pugliese C, Struthers C, Masters RG, Hendry PJ, Mesana T.
    Transplant Proc; 2007 Dec; 39(10):3334-9. PubMed ID: 18089382
    [Abstract] [Full Text] [Related]

  • 14. C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients.
    Caforio AL, Tona F, Piaserico S, Gambino A, Feltrin G, Fortina AB, Angelini A, Alaibac M, Bontorin M, Calzolari D, Peserico A, Thiene G, Iliceto S, Gerosa G.
    Transpl Int; 2005 Jan; 18(1):116-24. PubMed ID: 15612993
    [Abstract] [Full Text] [Related]

  • 15. Single time point measurement by C2 or C3 is highly predictive in cyclosporine area under the curve estimation immediately after lung transplantation.
    Hangler HB, Ruttmann E, Geltner C, Bucher B, Nagiller J, Laufer G, Mueller LC.
    Clin Transplant; 2008 Jan; 22(1):35-40. PubMed ID: 18217903
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic.
    Brunet M, Crespo M, Millán O, Serón D, Torregrosa V, Jiménez O, Moreso F, Martorell J, Grinyo JM, Oppenheimer F.
    Transplant Proc; 2007 Sep; 39(7):2160-2. PubMed ID: 17889124
    [Abstract] [Full Text] [Related]

  • 17. Clinical outcomes and C2 cyclosporin monitoring in maintenance renal transplant recipients: 1 year follow-up study.
    Marcén R, Villafruela JJ, Pascual J, Teruel JL, Ocaña J, Tenorio MT, Burgos FJ, Ortuño J.
    Nephrol Dial Transplant; 2005 Apr; 20(4):803-10. PubMed ID: 15687111
    [Abstract] [Full Text] [Related]

  • 18. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
    Thervet E, Pfeffer P, Scolari MP, Toselli L, Pallardó LM, Chadban S, Pilmore H, Connolly J, Buchler M, Schena FP, Carreño CA, Dandavino R, Cole E.
    Transplantation; 2003 Sep 27; 76(6):903-8. PubMed ID: 14508352
    [Abstract] [Full Text] [Related]

  • 19. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.
    Oellerich M, Armstrong VW, Streit F, Weber L, Tönshoff B.
    Clin Biochem; 2004 Jun 27; 37(6):424-8. PubMed ID: 15183289
    [Abstract] [Full Text] [Related]

  • 20. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation].
    Roy A, Grant DR, Kneteman NM, Tchervenkov JI, Levy GA, Tan A, Hendricks L.
    Ann Chir; 1998 Jun 27; 52(8):716-21. PubMed ID: 9846420
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.